Evidence map›Paper›PMID 25886717›Full record

ArticleAlzheimer disease and associated disorders

Trajectory of Mobility Decline by Type of Dementia.

Magdalena I Tolea, John C Morris, James E Galvin

Open access · greenAbstract read
In one paragraph

Article in Alzheimer disease and associated disorders. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Driving and Alzheimer's dementia or mild cognitive impairment: a systematic review of the existing guidelines emphasizing on the neurologist's role.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Pooled it
  3. Poor Gait Performance and Prediction of Dementia: Results From a Meta-Analysis.Journal of the American Medical Directors Association · 2016
    Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. ICAD: A Self-Supervised Autoregressive Approach for Multi-Context Anomaly Detection in Human Mobility Data.Proceedings of the ... ACM SIGSPATIAL International Conference on Advances in Geographic Information Systems : ACM GIS. ACM SIGSPATIAL International Conference on Advances in Geographic Information Systems · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Is There a Sex-Frailty Paradox in Dementia?The journal of nutrition, health & aging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Magdalena I Tolea*Departments of Neurology, Psychiatry, and Population Health, Alzheimer's Disease Center, Center for Cognitive Neurology, New York University School of Medicine, New York, NY †Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, MO.
John C Morris
James E Galvin
Software (Spain) · ESAlzheimer’s Disease Neuroimaging Initiative · US

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI FAGAN, ANNE · 1985 to 2019
$52.1M
PSYCHOSOCIAL COREP30AG008051 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SHAO, YONGZHAO · 1990 to 2019
$36.1M
Multicultural Community Dementia Screening.R01AG040211 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GALVIN, JAMES E · 2011 to 2018
$3.2M
NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG03991NIA NIH HHS P30 AG008051NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG05681NIA NIH HHS R01 AG040211
6 · The paper itself

Abstract

Cognitive and physical aspects of functionality are closely related. However, whether physical decline differs by dementia type and progression rate is debatable. To address these issues, we conducted a longitudinal study of 766 older adults whose physical performance and cognitive status were assessed annually with standard assessment tools [eg, Physical Performance Test, Clinical Dementia Rate (CDR)] for 8 years. Compared with participants who remained cognitively normal, those progressing to later-stage dementia (CDR=1) declined in their mobility by a factor of 2.82 (P<0.001), followed by those who maintained a later-stage diagnosis (slope=-1.84, P<0.001), those progressing from early-stage to later-stage (CDR=0.5 to CDR=1) dementia (slope=-1.20, P<0.001), and those who progressed to early-stage dementia (slope=-0.39, P=0.038) suggesting a steeper physical decline with dementia progression, particularly in those with the fastest disease progression. Although all types of dementia experienced mobility decline, those progressing to non-Alzheimer disease (AD) dementias, especially vascular dementia declined faster than those who remained normal (slope=-2.70, P<0.001) or progressed to AD (slope=-2.18, P<0.001). These associations were better captured by the gait/balance component of physical functionality. Our findings suggest that rapidly progressing dementia patients particularly those with non-AD subtypes should be targeted for interventions to maintain or improve gait/balance and prevent functional decline and disability although AD patients may also benefit.

Indexed as

Disease ProgressionMobility LimitationAgedAged, 80 and overDementiaDementia, VascularFemaleFrontotemporal DementiaGaitHumansLewy Body DiseaseLongitudinal StudiesMaleNeuropsychological Tests

Identifiers

PMID25886717
PMCPMC4592781
OpenAlexW2007039381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.